Shots:
- Denovo has licensed the global rights for idalopirdine including all rights to develop, manufacture and commercialize idalopirdine for all indications. Lundbeck gets an option to reacquire idalopirdine.
- If Lundbeck exercise the option, both the companies will share rights of the product in China and if not, Denovo will retain all global rights to the product
- Idalopirdine (DB109) is an oral antagonist of the serotonin (5-HT6) receptor and is hypothesized to be involved in AD, schizophrenia, and other indications. The therapy is currently being evaluated in multiple studies encompassing 2500+ subjects
Click here to read full press release/ article | Ref: PRNewswire | Image: PR Newswire
The post Denovo In-Licenses Lundbeck’s Idalopirdine for Alzheimer’s Disease and Other Indications first appeared on PharmaShots.
